AbbVie | ABBV - PE Price to Earnings


AbbVie reported 23.45 in PE Price to Earnings for its fiscal quarter ending in September of 2026.





Pe Change Date
AbbVie 23.45 0.51 Sep/2026
Abbott 34.85 10.99 Sep/2026
ALKERMES 262.4 126.59 Sep/2026
Amgen 18.6 0.53 Sep/2026
AstraZeneca 24.63 0.71 Sep/2026
Biogen 29.15 5.92 Sep/2026
BioMarin Pharmaceutical 53.62 32.55 Sep/2026
Bristol-Myers Squibb 10.44 5.7 Sep/2026
Eisai 30.24 3.68 Sep/2026
Eli Lilly 64.5 31.61 Sep/2026
Gilead Sciences 17.68 4.18 Sep/2026
GlaxoSmithKline 9.72 0.9 Sep/2026
J&J 25.86 3.57 Sep/2026
Medtronic 18.15 1.51 Jun/2026
Merck 34.36 2.11 Sep/2026
Neurocrine Biosciences 83.17 61.07 Sep/2026
Novartis 19.17 3.24 Sep/2026
Pacira 80.9 45.22 Sep/2026
Perrigo 21.11 6.34 Sep/2026
Pfizer 15.2 3.72 Sep/2026
Regeneron Pharmaceuticals 15.46 9.68 Jun/2026
Roche Holding 16.48 0.39 Jun/2026
Sanofi 22.34 3.38 Sep/2026
UCB 29.7 5.52 Dec/2025
United Therapeutics 19.41 0.26 Sep/2026
Vertex Pharmaceuticals 29.35 1.3 Sep/2026
Zoetis 11.38 0.8 Sep/2026